Inventiva SA
PAR:IVA
Inventiva SA
Other Operating Expenses
Inventiva SA
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Other Operating Expenses
-€671k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Operating Expenses
€112.3m
|
CAGR 3-Years
69%
|
CAGR 5-Years
76%
|
CAGR 10-Years
36%
|
|
|
Nanobiotix SA
PAR:NANO
|
Other Operating Expenses
€3.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Innate Pharma SA
PAR:IPH
|
Other Operating Expenses
€6.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
3%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Operating Expenses
-€17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other Operating Expenses
€609k
|
CAGR 3-Years
27%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Other Operating Expenses?
Other Operating Expenses
-671k
EUR
Based on the financial report for Jun 30, 2024, Inventiva SA's Other Operating Expenses amounts to -671k EUR.
What is Inventiva SA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
28%
You don't have any saved screeners yet